Choreo LLC Has $4.25 Million Holdings in Medtronic PLC $MDT

Choreo LLC raised its position in Medtronic PLC (NYSE:MDT) by 10.0% during the second quarter, according to its most recent filing with the SEC. The firm owned 48,378 shares of the medical technology company’s stock after purchasing an additional 4,413 shares during the period. Choreo LLC’s holdings in Medtronic were worth $4,249,000 as of its most recent filing with the SEC.

Other institutional investors also recently modified their holdings of the company. 1248 Management LLC acquired a new position in Medtronic in the first quarter valued at $26,000. Twin Tree Management LP acquired a new stake in Medtronic during the 1st quarter worth about $29,000. Activest Wealth Management raised its position in shares of Medtronic by 3,577.8% in the 1st quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after acquiring an additional 322 shares in the last quarter. GFG Capital LLC bought a new position in shares of Medtronic in the 2nd quarter worth about $36,000. Finally, True Wealth Design LLC lifted its stake in shares of Medtronic by 49.8% in the 2nd quarter. True Wealth Design LLC now owns 421 shares of the medical technology company’s stock valued at $37,000 after purchasing an additional 140 shares during the period. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Wells Fargo & Company raised their target price on Medtronic from $100.00 to $114.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Wall Street Zen upgraded Medtronic from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Barclays raised their price objective on shares of Medtronic from $109.00 to $111.00 and gave the stock an “overweight” rating in a research report on Thursday, November 20th. Piper Sandler reiterated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and twelve have given a Hold rating to the company. According to MarketBeat, Medtronic has a consensus rating of “Moderate Buy” and an average price target of $109.72.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the firm’s stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president owned 35,615 shares of the company’s stock, valued at approximately $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.26% of the stock is owned by corporate insiders.

Medtronic Price Performance

Shares of MDT opened at $105.13 on Thursday. The business’s fifty day moving average is $95.68 and its 200 day moving average is $91.39. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $106.33. The company has a quick ratio of 1.50, a current ratio of 2.01 and a debt-to-equity ratio of 0.54. The stock has a market cap of $134.85 billion, a P/E ratio of 28.96, a P/E/G ratio of 2.42 and a beta of 0.77.

Medtronic (NYSE:MDT) last released its quarterly earnings data on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, topping the consensus estimate of $1.31 by $0.05. Medtronic had a net margin of 13.63% and a return on equity of 14.61%. The firm had revenue of $8.96 billion for the quarter, compared to the consensus estimate of $8.86 billion. During the same quarter in the prior year, the company posted $1.26 earnings per share. The business’s revenue was up 6.6% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Sell-side analysts anticipate that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Company Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.